Clinical and laboratory characteristics of the studied patients according to FAB classification
Patient . | FAB . | Hb, mM . | WBC, × 109/L . | Platelets, × 109/L . | Megakaryocytes in bone marrow . | MPL, d . | PPR, × 109/d . | GCI . | TPO, pg/mL . | Karyotype . |
|---|---|---|---|---|---|---|---|---|---|---|
| 1 | RA | 7.2 | 8.0 | 70 | Increased | 5.3 | 150 | ND | ND | 46XY |
| 2 | RA | 7.0 | 6.3 | 71 | Normal | 7.4 | 45 | ND | ND | 46XX |
| 3 | RA | 4.8 | 5.5 | 88 | Normal | 5.3 | 160 | ND | ND | ND |
| 4 | RA | 6.5 | 2.8 | 23 | Increased | 5.0 | 50 | 41.0 | 118 | 46XY |
| 5 | RA | 5.8 | 4.4 | 33 | Normal | 4.0 | 63 | ND | ND | 47XY, +8 |
| 6 | RA | 6.5 | 0.8 | 50 | Decreased | 7.0 | 95 | ND | ND | 47XX, +5 |
| 7 | RA | 6.5 | 4.7 | 28 | Increased | 3.3 | 100 | ND | ND | ND |
| 8 | RA | 6.8 | 4.1 | 50 | Increased | 3.7 | 155 | ND | ND | ND |
| 9 | RA | 7.1 | 5.7 | 40 | Normal | 4.2 | 55 | ND | ND | ND |
| 10 | RA | 7.7 | 7.9 | 50 | Increased | 4.1 | 45 | ND | ND | 46XX |
| 11 | RA | 5.9 | 1.4 | 71 | Normal | 6.0 | 50 | 4.5 | 131 | ND |
| 12 | RA | 5.8 | 3.0 | 36 | Increased | 5.4 | 45 | 15.3 | 190 | 46XX, -7, +8 |
| 13 | RA | 7.4 | 2.7 | 88 | Normal | 6.3 | 95 | 5.2 | 138 | 46XY |
| 14 | RA | 6.7 | 2.9 | 77 | Normal | 4.4 | 130 | 5.2 | 102 | 46XX |
| 15 | RA | 6.5 | 2.2 | 55 | Normal | 6.1 | 55 | 8.7 | 256 | 46XX |
| 16 | RA | 4.8 | 4.0 | 13 | Decreased | 5.8 | 18 | 34.0 | 370 | 45X, -Y |
| 17 | RA | 4.8 | 5.4 | 54 | Normal | 4.2 | 110 | 3.9 | 361 | 46XY |
| 18 | RA | 4.0 | 5.9 | 29 | Increased | 4.3 | 105 | 15.0 | 384 | 46XY, i(17)(q10) |
| 19 | RA | 6.4 | 2.0 | 36 | Decreased | 6.2 | 55 | 5.9 | 130 | Multiple |
| 20 | RA | 8.6 | 4.2 | 29 | Normal | 8.0 | 40 | 7.3 | 135 | 46XY |
| 21 | RA | 7.5 | 2.2 | 37 | Increased | ND | ND | ND | ND | 46XX, del20p |
| 22 | RA | 5.2 | 1.4 | 110 | Normal | ND | ND | ND | ND | 46XX |
| 23 | RARS | 7.6 | 4.2 | 115 | Increased | ND | ND | ND | ND | 45X, -Y |
| 24 | RAEB | 5.7 | 8.8 | 75 | Normal | 3.5 | 210 | ND | ND | ND |
| 25 | RAEB | 6.0 | 4.2 | 65 | Normal | 5.5 | 75 | 14.5 | 95 | 46XX |
| 26 | RAEB | 5.8 | 2.4 | 46 | Decreased | 3.3 | 100 | 4.2 | 869 | 45XY, -7 |
| 27 | RAEB | 5.9 | 1.6 | 52 | Increased | 7.8 | 60 | 3.4 | 140 | 46XY |
| 28 | RAEB | 5.8 | 3.0 | 26 | Normal | 4.6 | 60 | 21.7 | 180 | 46XY |
| 29 | RAEB | 5.8 | 3.7 | 78 | Normal | 3.0 | 175 | 5.2 | ND | 46XY |
| 30 | RAEB | 8.8 | 9.0 | 14 | Decreased | 3.7 | 45 | 17.1 | ND | ND |
| 31 | RAEB | 5.9 | 5.6 | 302 | Normal | ND | ND | ND | ND | 45X, -Y |
| 32 | RAEB | 5.6 | 8.0 | 50 | Decreased | ND | ND | ND | ND | Multiple |
| 33 | CMML | 9.1 | 12.6 | 17 | Increased | 6.0 | 15 | 64.4 | 44 | ND |
| 34 | CMML | 8.2 | 7.4 | 30 | Normal | 5.7 | 35 | 13.4 | 49 | ND |
| 35 | CMML | 6.8 | 5.5 | 98 | Normal | 4.1 | 210 | 2.7 | 315 | 46XY |
Patient . | FAB . | Hb, mM . | WBC, × 109/L . | Platelets, × 109/L . | Megakaryocytes in bone marrow . | MPL, d . | PPR, × 109/d . | GCI . | TPO, pg/mL . | Karyotype . |
|---|---|---|---|---|---|---|---|---|---|---|
| 1 | RA | 7.2 | 8.0 | 70 | Increased | 5.3 | 150 | ND | ND | 46XY |
| 2 | RA | 7.0 | 6.3 | 71 | Normal | 7.4 | 45 | ND | ND | 46XX |
| 3 | RA | 4.8 | 5.5 | 88 | Normal | 5.3 | 160 | ND | ND | ND |
| 4 | RA | 6.5 | 2.8 | 23 | Increased | 5.0 | 50 | 41.0 | 118 | 46XY |
| 5 | RA | 5.8 | 4.4 | 33 | Normal | 4.0 | 63 | ND | ND | 47XY, +8 |
| 6 | RA | 6.5 | 0.8 | 50 | Decreased | 7.0 | 95 | ND | ND | 47XX, +5 |
| 7 | RA | 6.5 | 4.7 | 28 | Increased | 3.3 | 100 | ND | ND | ND |
| 8 | RA | 6.8 | 4.1 | 50 | Increased | 3.7 | 155 | ND | ND | ND |
| 9 | RA | 7.1 | 5.7 | 40 | Normal | 4.2 | 55 | ND | ND | ND |
| 10 | RA | 7.7 | 7.9 | 50 | Increased | 4.1 | 45 | ND | ND | 46XX |
| 11 | RA | 5.9 | 1.4 | 71 | Normal | 6.0 | 50 | 4.5 | 131 | ND |
| 12 | RA | 5.8 | 3.0 | 36 | Increased | 5.4 | 45 | 15.3 | 190 | 46XX, -7, +8 |
| 13 | RA | 7.4 | 2.7 | 88 | Normal | 6.3 | 95 | 5.2 | 138 | 46XY |
| 14 | RA | 6.7 | 2.9 | 77 | Normal | 4.4 | 130 | 5.2 | 102 | 46XX |
| 15 | RA | 6.5 | 2.2 | 55 | Normal | 6.1 | 55 | 8.7 | 256 | 46XX |
| 16 | RA | 4.8 | 4.0 | 13 | Decreased | 5.8 | 18 | 34.0 | 370 | 45X, -Y |
| 17 | RA | 4.8 | 5.4 | 54 | Normal | 4.2 | 110 | 3.9 | 361 | 46XY |
| 18 | RA | 4.0 | 5.9 | 29 | Increased | 4.3 | 105 | 15.0 | 384 | 46XY, i(17)(q10) |
| 19 | RA | 6.4 | 2.0 | 36 | Decreased | 6.2 | 55 | 5.9 | 130 | Multiple |
| 20 | RA | 8.6 | 4.2 | 29 | Normal | 8.0 | 40 | 7.3 | 135 | 46XY |
| 21 | RA | 7.5 | 2.2 | 37 | Increased | ND | ND | ND | ND | 46XX, del20p |
| 22 | RA | 5.2 | 1.4 | 110 | Normal | ND | ND | ND | ND | 46XX |
| 23 | RARS | 7.6 | 4.2 | 115 | Increased | ND | ND | ND | ND | 45X, -Y |
| 24 | RAEB | 5.7 | 8.8 | 75 | Normal | 3.5 | 210 | ND | ND | ND |
| 25 | RAEB | 6.0 | 4.2 | 65 | Normal | 5.5 | 75 | 14.5 | 95 | 46XX |
| 26 | RAEB | 5.8 | 2.4 | 46 | Decreased | 3.3 | 100 | 4.2 | 869 | 45XY, -7 |
| 27 | RAEB | 5.9 | 1.6 | 52 | Increased | 7.8 | 60 | 3.4 | 140 | 46XY |
| 28 | RAEB | 5.8 | 3.0 | 26 | Normal | 4.6 | 60 | 21.7 | 180 | 46XY |
| 29 | RAEB | 5.8 | 3.7 | 78 | Normal | 3.0 | 175 | 5.2 | ND | 46XY |
| 30 | RAEB | 8.8 | 9.0 | 14 | Decreased | 3.7 | 45 | 17.1 | ND | ND |
| 31 | RAEB | 5.9 | 5.6 | 302 | Normal | ND | ND | ND | ND | 45X, -Y |
| 32 | RAEB | 5.6 | 8.0 | 50 | Decreased | ND | ND | ND | ND | Multiple |
| 33 | CMML | 9.1 | 12.6 | 17 | Increased | 6.0 | 15 | 64.4 | 44 | ND |
| 34 | CMML | 8.2 | 7.4 | 30 | Normal | 5.7 | 35 | 13.4 | 49 | ND |
| 35 | CMML | 6.8 | 5.5 | 98 | Normal | 4.1 | 210 | 2.7 | 315 | 46XY |
FAB indicates French-American-British; Hb, hemoglobin; WBC, white blood cell; MPL, mean platelet life; PPR, platelet production rate; GCI, glycocalicin index; TPO, thrombopoietin; Multiple, 3 or more abnormalities; and ND, not done. Normal values: MPL, 9.2 ± 1.4 days; PPR, 220 ± 65 × 109/day; GCI, 0.7 ± 0.2; and TPO, 118 ± 33 pg/mL.